New insider activity at Greenwich LifeSciences ( (GLSI) ) has taken place on April 8, 2025.
CEO and CFO Snehal Patel has made a significant investment in Greenwich LifeSciences by purchasing 5,500 shares of the company’s stock, valued at $48,015.
Recent Updates on GLSI stock
Greenwich LifeSciences has reported significant progress in its Phase III FLAMINGO-01 clinical trial, evaluating the immunotherapy GLSI-100 for preventing breast cancer recurrences. The trial’s preliminary data indicates positive immune responses in both HLA-A*02 and non-HLA-A*02 patient groups, leading to an expansion of the non-HLA-A*02 arm and potentially transforming it into a second Phase III trial. This expansion could increase the market potential for GLSI-100, with the company filing new patent claims that might double the eligible patient population. Additionally, no serious adverse events have been reported, and the trial’s safety profile remains favorable. However, the company has delayed its yearly report filing due to a significant increase in R&D expenses, impacting its financial statements. These developments have influenced analysts’ perspectives on the stock, focusing on the trial’s promising data and the financial implications of increased R&D spending.
More about Greenwich LifeSciences
YTD Price Performance: -24.79%
Average Trading Volume: 46,601
Technical Sentiment Signal: Strong Buy
Current Market Cap: $116.1M